These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 34535564)

  • 1. Deconstructing the Pharmacological Contribution of Sphingosine-1 Phosphate Receptors to Mouse Models of Multiple Sclerosis Using the Species Selectivity of Ozanimod, a Dual Modulator of Human Sphingosine 1-Phosphate Receptor Subtypes 1 and 5.
    Selkirk JV; Dines KC; Yan YG; Ching N; Dalvie D; Biswas S; Bortolato A; Schkeryantz JM; Lopez C; Ruiz I; Hargreaves R
    J Pharmacol Exp Ther; 2021 Dec; 379(3):386-399. PubMed ID: 34535564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Central Modulation of Selective Sphingosine-1-Phosphate Receptor 1 Ameliorates Experimental Multiple Sclerosis.
    Musella A; Gentile A; Guadalupi L; Rizzo FR; De Vito F; Fresegna D; Bruno A; Dolcetti E; Vanni V; Vitiello L; Bullitta S; Sanna K; Caioli S; Balletta S; Nencini M; Buttari F; Stampanoni Bassi M; Centonze D; Mandolesi G
    Cells; 2020 May; 9(5):. PubMed ID: 32455907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ozanimod: A Review in Relapsing Forms of Multiple Sclerosis.
    Nie T; Syed YY
    CNS Drugs; 2024 Nov; 38(11):931-941. PubMed ID: 39368032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.
    Scott FL; Clemons B; Brooks J; Brahmachary E; Powell R; Dedman H; Desale HG; Timony GA; Martinborough E; Rosen H; Roberts E; Boehm MF; Peach RJ
    Br J Pharmacol; 2016 Jun; 173(11):1778-92. PubMed ID: 26990079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absorption, Metabolism, and Excretion, In Vitro Pharmacology, and Clinical Pharmacokinetics of Ozanimod, a Novel Sphingosine 1-Phosphate Receptor Modulator.
    Surapaneni S; Yerramilli U; Bai A; Dalvie D; Brooks J; Wang X; Selkirk JV; Yan YG; Zhang P; Hargreaves R; Kumar G; Palmisano M; Tran JQ
    Drug Metab Dispos; 2021 May; 49(5):405-419. PubMed ID: 33674268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro assessment of the binding and functional responses of ozanimod and its plasma metabolites across human sphingosine 1-phosphate receptors.
    Selkirk JV; Yan YG; Ching N; Paget K; Hargreaves R
    Eur J Pharmacol; 2023 Feb; 941():175442. PubMed ID: 36470447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Competitive Binding of Ozanimod and Other Sphingosine 1-Phosphate Receptor Modulators at Receptor Subtypes 1 and 5.
    Selkirk JV; Bortolato A; Yan YG; Ching N; Hargreaves R
    Front Pharmacol; 2022; 13():892097. PubMed ID: 35784713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ozanimod: First Approval.
    Lamb YN
    Drugs; 2020 Jun; 80(8):841-848. PubMed ID: 32385738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ozanimod-mediated remission in experimental autoimmune encephalomyelitis is associated with enhanced activity of CNS CD27
    Kamyan D; Hassane M; Alnaqbi A; Souid AK; Rasbi ZA; Tahrawi AA; Shamsi MA
    Front Immunol; 2024; 15():1230735. PubMed ID: 38533505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel compounds with dual S1P receptor agonist and histamine H
    Imeri F; Stepanovska Tanturovska B; Zivkovic A; Enzmann G; Schwalm S; Pfeilschifter J; Homann T; Kleuser B; Engelhardt B; Stark H; Huwiler A
    Neuropharmacology; 2021 Mar; 186():108464. PubMed ID: 33460688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ozanimod for the treatment of relapsing forms of multiple sclerosis.
    Kuczynski AM; Oh J
    Neurodegener Dis Manag; 2021 Jun; 11(3):207-220. PubMed ID: 34011158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ASP4058, a novel agonist for sphingosine 1-phosphate receptors 1 and 5, ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile.
    Yamamoto R; Okada Y; Hirose J; Koshika T; Kawato Y; Maeda M; Saito R; Hattori K; Harada H; Nagasaka Y; Morokata T
    PLoS One; 2014; 9(10):e110819. PubMed ID: 25347187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morpholino Analogues of Fingolimod as Novel and Selective S1P
    Stepanovska B; Zivkovic A; Enzmann G; Tietz S; Homann T; Kleuser B; Engelhardt B; Stark H; Huwiler A
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
    McGinley MP; Cohen JA
    Lancet; 2021 Sep; 398(10306):1184-1194. PubMed ID: 34175020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effect of the sphingosine-1 phosphate receptor agonist siponimod on disrupted blood brain barrier function.
    Spampinato SF; Merlo S; Sano Y; Kanda T; Sortino MA
    Biochem Pharmacol; 2021 Apr; 186():114465. PubMed ID: 33577891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visualizing Sphingosine-1-Phosphate Receptor 1(S1P
    Hashemi E; Yoseph E; Tsai HC; Moreno M; Yeh LH; Mehta SB; Kono M; Proia R; Han MH
    Cell Mol Neurobiol; 2023 Apr; 43(3):1219-1236. PubMed ID: 35917044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ponesimod inhibits astrocyte-mediated neuroinflammation and protects against cingulum demyelination via S1P
    Kihara Y; Jonnalagadda D; Zhu Y; Ray M; Ngo T; Palmer C; Rivera R; Chun J
    FASEB J; 2022 Feb; 36(2):e22132. PubMed ID: 34986275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The sphingosine-1-phosphate receptor 1 modulator ponesimod repairs cuprizone-induced demyelination and induces oligodendrocyte differentiation.
    Willems E; Schepers M; Piccart E; Wolfs E; Hellings N; Ait-Tihyaty M; Vanmierlo T
    FASEB J; 2024 Jan; 38(2):e23413. PubMed ID: 38243760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of sphingosine-1-phosphate in ulcerative colitis.
    Argollo M; Furfaro F; Gilardi D; Roda G; Allocca M; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2020 Apr; 20(4):413-420. PubMed ID: 32093531
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS.
    Harris S; Tran JQ; Southworth H; Spencer CM; Cree BAC; Zamvil SS
    Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32737072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.